merged_variant-bio-novo-nordisk-indigenous-revenue-sharing.txt
<other>First, I will analyze the article to find the relevant information for each question.</other>
<question_number>1</question_number>
<answer>N/A</answer>
<other>The article does not specify the percentage of Variant Bio's project budget allocated to scholarships and scientific conferences for Indigenous people in French Polynesia.</other>
<question_number>2</question_number>
<answer>$100,000</answer>
<other>Variant Bio invested $100,000 in local health organizations in New Zealand as a result of their findings related to a fatal drug reaction observed in certain Asian populations.</other>
<question_number>3</question_number>
<answer>8</answer>
<other>Dr. Wasik visited 8 countries during Variant Bio's initial seed funding phase.</other>
<question_number>4</question_number>
<answer>N/A</answer>
<other>The article does not specify the month and year when Dr. Castel and Dr. Wasik secured their initial $50 million in funding.</other>
<question_number>5</question_number>
<answer>Lux Capital</answer>
<answer>A venture capital firm in New York City provided the initial financial backing for Variant Bio.</answer>
<question_number>6</question_number>
<answer>Nagoya Protocol</answer>
<answer>The international agreement referenced is the Nagoya Protocol under the United Nations Convention on Biological Diversity.</answer>
<question_number>7</question_number>
<answer>gout</answer>
<answer>Variant Bio's research in French Polynesia addressed the disease gout.</other>
<question_number>8</question_number>
<answer>Krystal Tsosie</answer>
<answer>Krystal Tsosie is the Arizona State University geneticist and bioethicist who criticized the Samoan research and runs a nonprofit genetic repository for Indigenous people.</other>
<question_number>9</question_number>
<answer>geneticists</answer>
<answer>The original professions of the two founders of Variant Bio were geneticists.</other>
<question_number>10</question_number>
<answer>N/A</answer>
<other>The article does not mention the specific name of a drug developed by Novo Nordisk in collaboration with Variant Bio targeting the Maori population.</other>
<question_number>11</question_number>
<answer>4 percent</answer>
<answer>4 percent of Variant Bio’s revenue is designated for sharing with indigenous communities as mentioned in the deal with Novo Nordisk.</other>
<question_number>12</question_number>
<answer>Karitiana tribe</answer>
<answer>The Karitiana tribe's experience with unauthorized profit from DNA samples is cited as a warning against exploitation.</other>
<question_number>13</question_number>
<answer>Dr. Stephane Castel</answer>
<answer>Dr. Stephane Castel led the company’s discussions with Maori and Pacific Islander communities during their 2019 outreach.</other>
<question_number>14</question_number>
<answer>up to 10 percent</answer>
<answer>Up to 10 percent of a project’s budget is earmarked to support community programs and local health organizations.</other>
<question_number>15</question_number>
<answer>Lux Capital</answer>
<answer>Lux Capital is the venture capital firm noted for providing the $16 million seed funding to Variant Bio.</other>
<question_number>16</question_number>
<answer>Keolu Fox</answer>
<answer>Keolu Fox is the outspoken geneticist from the University of California, San Diego, who criticized earlier methods of collaborating with indigenous communities.</other>
<question_number>17</question_number>
<answer>blood and DNA being sold for $85 per sample</answer>
<answer>The misuse of genetic material reported by a member of the Karitiana tribe was the sale of their blood and DNA for $85 per sample.</other>
<question_number>18</question_number>
<answer>Inuit populations in Greenland</answer>
<answer>The Arctic indigenous group mentioned as a source of novel gene variants affecting metabolism is the Inuit populations in Greenland.</other>
<question_number>19</question_number>
<answer>Nagoya Protocol</answer>
<answer>The Nagoya Protocol is the international agreement referenced as having excluded human genomic information from its benefit-sharing mandates.</other>
<question_number>20</answer>
<answer>drugs developed from the partnership</answer>
<answer>Variant Bio decided to protect the drugs developed from the partnership instead of the genes themselves.</other>